|02/23/18||Vermillion to Present at the 2018 BTIG Healthcare Conference|
|AUSTIN, Texas, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to participate in BTIG’s 2018 Healthcare Conference from February 28, 2018 through March 1, 2018 in Snowbird, Utah. BTIG’s annual conference will bring together more than 100 leading healthcare companies with ins... |
|02/05/18||Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents|
|AUSTIN, Texas, Feb. 5, 2018 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1™ and Overa™.
The first, US Patent No. 9,816,995, entitled "Biomarker for ovarian cancer CTAP3-related proteins," describes and claims panels of biomarkers associated with ovarian cancer.
The second patent, US Patent No. 9,846,158, entitled "Predictive biomarkers for ovarian cancer... |
|01/18/18||Vermillion Announces Agreement with BlueCross BlueShield of Illinois|
|AUSTIN, Texas, Jan. 18, 2018 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with BlueCross BlueShield of Illinois.
"ASPiRA Labs is excited to announce a contracted agreement for OVA1 with BCBS of Illinois, effective immediately," said Fred Ferrara, Chief Operating Officer of Vermillion... |